...By Paul Bonanos, Associate Editor Merck’s roster of COVID-19 countermeasures gained via deals continued to shrink... ...HHS and the Department of Defense.A Merck spokesperson declined to tell BioCentury how much money Merck... ...patients following stem cell transplantation. Merck’s spokesperson said that trial is unaffected by Thursday’s decision.Since Merck’s...
...study, INDUCE-4, was evaluating feladilimab vs. placebo in combination with pembrolizumab and chemotherapy. GSK is partnered with Merck & Co. Inc....
...By Paul Bonanos, Associate Editor Merck’s roster of COVID-19 countermeasures gained via deals continued to shrink... ...HHS and the Department of Defense.A Merck spokesperson declined to tell BioCentury how much money Merck... ...patients following stem cell transplantation. Merck’s spokesperson said that trial is unaffected by Thursday’s decision.Since Merck’s...
...study, INDUCE-4, was evaluating feladilimab vs. placebo in combination with pembrolizumab and chemotherapy. GSK is partnered with Merck & Co. Inc....